Please try another search
For the fiscal year ended 31 December 2020, Gene Biotherapeutics Inc revenues was not reported. Net loss totaled $518K vs. income of $867K. Net loss reflects Selling, general and administrative increase of 76% to $1M (expense), Interest expense increase of 31% to $57K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.06 to -$0.02.
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -1.08 | -0.39 | 0.42 | -0.15 |
Net Income | -0.44 | -0.36 | 0.44 | -0.15 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 0.57 | 0.97 | 1.34 | 0.13 |
Total Liabilities | 4.44 | 4.41 | 4.41 | 4.57 |
Total Equity | -3.88 | -3.43 | -3.07 | -4.44 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -1.13 | -0.8 | -0.32 | -0.09 |
Cash From Investing Activities | -0 | -0 | ||
Cash From Financing Activities | 1.52 | 1.58 | 1.63 | 0.1 |
Net Change in Cash | 0.39 | 0.78 | 1.31 | 0 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review